Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 7/20 | 0.55 |
| ▸ | CASP1 | P29466 | 5/20 | 0.55 |
| ▸ | CASP9 | P55211 | 5/20 | 0.55 |
| ▸ | CASP7 | P55210 | 5/20 | 0.55 |
| ▸ | CASP4 | P49662 | 3/20 | 0.55 |
| ▸ | CASP10 | Q92851 | 3/20 | 0.55 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 4/20 | 0.49 |
| ▸ | LGMN | Q99538 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | CASP5 | P51878 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022177 | 0.97 | CASP3 (0.54) | CASP3CASP1CASP9CASP7CASP4 | |
| SCHEMBL4022889 | 0.91 | LGMN (0.54) | CASP3CASP1CASP9CASP7CASP4 | |
| SCHEMBL13962629 | 0.90 | CTSL (0.47) | CASP3CASP1CASP9CASP7CASP4 | |
| SCHEMBL13938879 | 0.90 | CTSL (0.47) | CASP3CASP1CASP9CASP7CASP4 | |
| SCHEMBL4014017 | 0.88 | CASP3 (0.48) | CASP3CASP1CASP9CASP7CASP4 | |
| SCHEMBL4022491 | 0.88 | CASP3 (0.60) | CASP3CASP1CASP9CASP7CASP4 | |
| SCHEMBL4017547 | 0.87 | CASP3 (0.58) | CASP3CASP1CASP9CASP7CASP4 | |
| SCHEMBL20740998 | 0.85 | CASP3 (0.62) | CASP3CASP1CASP9CASP7CASP4 | |
| SCHEMBL20760721 | 0.85 | CASP3 (0.62) | CASP3CASP1CASP9CASP7CASP4 | |
| SCHEMBL20603601 | 0.85 | CASP3 (0.62) | CASP3CASP1CASP9CASP7CASP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482379-B2 | Propenoyl hydrazides | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| US-20050256058-A1 | Propenoyl hydrazides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256058-A1 | Propenoyl hydrazides | DNPEP, HPN, PREP | CASP3 487/4885CASP1 927/4885CASP9 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.